CVS Health Corp

CVS Health Corp (CVS-N) vs Walgreen Boots Alliance (WBA-O) or stay out of health care?He prefers Walgreen between the two, due to their Rite Aid acquisition. They feel that a safer option is AmerisourceBergen (ABC-N) as they are more on the distribution side. (Analysts’ price target is $89)

CVS Health Corp (CVS-N) vs Walgreen Boots Alliance (WBA-O) or stay out of health care?He prefers Walgreen between the two, due to their Rite Aid acquisition. They feel that a safer option is AmerisourceBergen (ABC-N) as they are more on the distribution side. (Analysts’ price target is $89)

(A Top Pick Feb. 16/17, Down 12%)Sold his shares last summer. Too much regulatory uncertainty and risk. more than he bargained for. Likes home healthcare, but the regulatory risk turns him off. Amazon going into the space scares the hell out of everyone, doesn't it?

(A Top Pick Feb. 16/17, Down 12%)Sold his shares last summer. Too much regulatory uncertainty and risk. more than he bargained for. Likes home healthcare, but the regulatory risk turns him off. Amazon going into the space scares the hell out of everyone, doesn't it?

A lot of pressure from Amazon getting into CVS' space, but confident CVS will emerge well. CVS will fight back. But don't get too speculative on events (Amazon) that could happen. ROIC consistent. Good valuation. He has faith in CVS.

A lot of pressure from Amazon getting into CVS' space, but confident CVS will emerge well. CVS will fight back. But don't get too speculative on events (Amazon) that could happen. ROIC consistent. Good valuation. He has faith in CVS.

It is not like Shoppers Drug Mart like some people believe it is. They are more an integrated health care company rather than retail. Some of the issues they had with the CVS part of the business have stabilized. It makes sense in the Health Care space to be vertically integrated. Over the long run is going to do well particularly if they integrate ETNA well. On top of that the tax cuts will help them as they are mostly domestic (Analysts' price target $89).

It is not like Shoppers Drug Mart like some people believe it is. They are more an integrated health care company rather than retail. Some of the issues they had with the CVS part of the business have stabilized. It makes sense in the Health Care space to be vertically integrated. Over the long run is going to do well particularly if they integrate ETNA well. On top of that the tax cuts will help them as they are mostly domestic (Analysts' price target $89).

The thing with this, as we have seen with a lot of stocks, is the Amazon factor. If you don't own Amazon, you are kind of behind the curve because it has done so well. However, on the flipside, if you own anything that Amazon is remotely touching, you are going to get penalized. This company falls into that category. It screens great on any kind of a value metric, but there is this huge overhang in the industry. She doesn't want to own anything that is even remotely spoken about that has an Amazon connection.

The thing with this, as we have seen with a lot of stocks, is the Amazon factor. If you don't own Amazon, you are kind of behind the curve because it has done so well. However, on the flipside, if you own anything that Amazon is remotely touching, you are going to get penalized. This company falls into that category. It screens great on any kind of a value metric, but there is this huge overhang in the industry. She doesn't want to own anything that is even remotely spoken about that has an Amazon connection.

The acquisition is a big one and because of the size there is some fear they can’t get it done. There is more risk to this deal than normal. It is in no man’s land otherwise. It has not got strong price momentum, but has a good balance sheet.

The acquisition is a big one and because of the size there is some fear they can’t get it done. There is more risk to this deal than normal. It is in no man’s land otherwise. It has not got strong price momentum, but has a good balance sheet.

About 2 or 3 months ago, this got hit by the Amazon affect, and the stock fell to $66, and is now at $79. This has a positive transit of EBV +3, which is a Buy signal. His model price is $100.70, 27% upside. A good price if you are looking at buying this.

About 2 or 3 months ago, this got hit by the Amazon affect, and the stock fell to $66, and is now at $79. This has a positive transit of EBV +3, which is a Buy signal. His model price is $100.70, 27% upside. A good price if you are looking at buying this.

Just made the acquisition of Aetna, which is still pending approval. There is a consistency of the business and they're spinning off an incredible amount of free cash flow and buying back a ton of stock. Had a bit of volatility through the end of the year, because of an article regarding Aetna and the multiple they were going to have to pay. There was also concern about Amazon (AMZN-Q) entering the pharmacy space. This is inexpensive relative to the rest of the market, trading at 12X earnings. Dividend yield of 2.5%. (Analysts' price target is $88.)

Just made the acquisition of Aetna, which is still pending approval. There is a consistency of the business and they're spinning off an incredible amount of free cash flow and buying back a ton of stock. Had a bit of volatility through the end of the year, because of an article regarding Aetna and the multiple they were going to have to pay. There was also concern about Amazon (AMZN-Q) entering the pharmacy space. This is inexpensive relative to the rest of the market, trading at 12X earnings. Dividend yield of 2.5%. (Analysts' price target is $88.)

Had owned this, but sold it to buy something else. They are going to have a big benefit from tax reform, although they acquired Aetna. That is going to really transform them. It is no longer going to be a retailer and a pharmaceutical benefits manager, it is also going to have healthcare plans. Taking on a lot of debt to make the acquisition and there is no guarantee of success. Although it looks cheap, it is not one he is excited about getting into at the moment.

Had owned this, but sold it to buy something else. They are going to have a big benefit from tax reform, although they acquired Aetna. That is going to really transform them. It is no longer going to be a retailer and a pharmaceutical benefits manager, it is also going to have healthcare plans. Taking on a lot of debt to make the acquisition and there is no guarantee of success. Although it looks cheap, it is not one he is excited about getting into at the moment.

Partly a drugstore, partly a long-term health care business and partly a pharmaceutical benefits business. The stock has about a 7% free cash flow yield and a 2.7% dividend yield. Trading at about 11X earnings. They just bought Aetna and vertically integrating the company. It's not about selling drugs and drug store stuff or having fees for services, it is much more about being a healthcare company. They may have to do an equity issue which makes a lot of sense. This makes it a company that Amazon (AMZ-Q) would be hard to compete with. (Analysts' price target is $85.50.)

Partly a drugstore, partly a long-term health care business and partly a pharmaceutical benefits business. The stock has about a 7% free cash flow yield and a 2.7% dividend yield. Trading at about 11X earnings. They just bought Aetna and vertically integrating the company. It's not about selling drugs and drug store stuff or having fees for services, it is much more about being a healthcare company. They may have to do an equity issue which makes a lot of sense. This makes it a company that Amazon (AMZ-Q) would be hard to compete with. (Analysts' price target is $85.50.)

(A Top Pick Dec 19/16.Down 7%.) People are afraid Amazon is going to come in and take their space. That is unlikely to happen. They have 10,000 locations in the US along with 1600 in Target stores and 1200 in mini-clinics. A wonderful platform to capture the patient experience, which is exactly what they are trying to do.

(A Top Pick Dec 19/16.Down 7%.) People are afraid Amazon is going to come in and take their space. That is unlikely to happen. They have 10,000 locations in the US along with 1600 in Target stores and 1200 in mini-clinics. A wonderful platform to capture the patient experience, which is exactly what they are trying to do.

She is going to continue holding this, even though Amazon (AMZN-Q) may enter the mail order drug delivery space. Feels they are well positioned. They have the infrastructure and their PBM service, so can compete if they have to. The multiple has really contracted, trading at about 12X forward earnings. There are rumours that CVS may buy a health insurance company, possibly Aetna, which has caused the stock to pull back. They are virtually integrating in that whole chain, and will eventually derive more scripts and more services into their retail network, which will help lower overall hospital costs.

She is going to continue holding this, even though Amazon (AMZN-Q) may enter the mail order drug delivery space. Feels they are well positioned. They have the infrastructure and their PBM service, so can compete if they have to. The multiple has really contracted, trading at about 12X forward earnings. There are rumours that CVS may buy a health insurance company, possibly Aetna, which has caused the stock to pull back. They are virtually integrating in that whole chain, and will eventually derive more scripts and more services into their retail network, which will help lower overall hospital costs.

This has responded to the Amazon (AMZN-Q) factor. They are rumoured to be talking to Aetna for a takeover. That would create a vertically integrated business model. If they can create a model where the patient experience is owned by the CVS group, then people are less and less likely to want to interrupt that relationship. That is the response we are starting to see.

This has responded to the Amazon (AMZN-Q) factor. They are rumoured to be talking to Aetna for a takeover. That would create a vertically integrated business model. If they can create a model where the patient experience is owned by the CVS group, then people are less and less likely to want to interrupt that relationship. That is the response we are starting to see.

The biggest problem is Amazon. You have to ask, how does Amazon come into this type of market and destroy a business. If you’re in industries that Amazon can touch, there is a lot of fear. It’ll be hard to say how tough CVS's moat is and how they will be able to compete going forward. This screens very well on a valuation basis, and is compelling to look at, but with the Amazon factor of going into different industries and being very competitive, that is on a lot of people's minds. That overhang can be there for quite a while.

The biggest problem is Amazon. You have to ask, how does Amazon come into this type of market and destroy a business. If you’re in industries that Amazon can touch, there is a lot of fear. It’ll be hard to say how tough CVS's moat is and how they will be able to compete going forward. This screens very well on a valuation basis, and is compelling to look at, but with the Amazon factor of going into different industries and being very competitive, that is on a lot of people's minds. That overhang can be there for quite a while.

There is a lot happening. You have everything from an Amazon factor with the PBM's, to the challenging brick-and-mortar at the front. He’s stayed away from staples category this fall. It hasn't worked technically. There’s been a number of headwinds. If you own this, consider using it as an offset to your gains.

There is a lot happening. You have everything from an Amazon factor with the PBM's, to the challenging brick-and-mortar at the front. He’s stayed away from staples category this fall. It hasn't worked technically. There’s been a number of headwinds. If you own this, consider using it as an offset to your gains.

This site is used by investors to track what stock experts say.
Stockchase is useful as an online investing tool for due diligence, and for getting a feel for how companies are thought of by investment experts. This site should not be your only resource or reference, but it should be one of the investing tools in your arsenal for wise investing in the stock market. Stockchase draws only on what has been discussed by individuals who appear on business television programs, in particular the Business News Network. Stockchase, in its reporting, neither recommends nor promotes any investment strategies that have been discussed.

We are human and can make mistakes. Help us fix any errors.
If you see something that you know is not right or if there is a problem with the site, please email us at hello@stockchase.com.